Lupin Launches Authorized Generic Version of Alinia®

Global pharma major, Lupin Limited (Lupin), has announced the launch of the authorized generic version of Alinia® (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C.

Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.

Nitazoxanide Tablets, 500 mg (RLD: Alinia®) had estimated annual sales of USD 56 million in the U.S. (IQVIA MAT January 2021).

Shares of LUPIN LTD. was last trading in BSE at Rs.1031.15 as compared to the previous close of Rs. 1050.45. The total number of shares traded during the day was 63372 in over 2596 trades.

The stock hit an intraday high of Rs. 1057.7 and intraday low of 1014.65. The net turnover during the day was Rs. 65718217.

Source : Equity Bulls

Keywords